TrialJournal of clinical psychopharmacology

52-Week Open-Label Safety and Tolerability Study of Centanafadine Sustained Release in Adults With Attention-Deficit/Hyperactivity Disorder.

Gregory W Mattingly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.